Illumina has appointed Scott Gottlieb to its board of directors. Gottlieb is currently a special partner at New Enterprises Associates and a resident fellow at the American Enterprise Institute. He previously served as the 23rd commissioner of the US Food and Drug Administration form 2017 to 2019. Prior to joining the US FDA as commissioner, Gottlieb was a clinical assistant professor at the New York University School of Medicine.
Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.